Peripheral neuropathy associated with treatment for multidrug-resistant tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 7, Issue 4, 2003, Pages 347-353

  Shin, Sonya S ^a,b   Hyson, A M ^b   Castaneda C ^c   Sanchez E ^d   Alcantara F ^e   Mitnick, C D ^b   Smith Fawzi, M C ^b   Bayona, J ^b,e   Farmer, P E ^a,b   Kim, J Y ^a,b   Furin, J J ^e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^d MINISTERIO DE SALUD   (Peru)

^e PARTNERS IN HEALTH   (United States)

Author keywords

MDR TB; Peripheral neuropathy; Peru; Tuberculosis

Indexed keywords

CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOMYCIN;

ADULT; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DOSE CALCULATION; ELECTROMYOGRAPHY; FEMALE; HUMAN; INCIDENCE; LEG; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; NEUROPATHIC PAIN; PATIENT CARE; PERIPHERAL NEUROPATHY; PERU; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TIME; TUBERCULOSIS;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTITUBERCULAR AGENTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ELECTROMYOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; PERU; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 12444329969     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Farmer P E, Furin J J, Shin S S. The clinical management of multidrug-resistant tuberculosis. J Respir Dis 2000; 21: 53-56.
2. Farmer P E, Kim J Y, Mitnick C D, Timperi R. Responding to outbreaks of MDRTB: introducing DOTS-Plus. In: Reichman L B, Hershfield E S, eds. Tuberculosis: a comprehensive international approach. 2nd ed. New York, NY: Marcel Dekker Inc., 2000: 447-469.
3. Mitnick C D, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. New Engl J Med 2003; 348: 119-128.
4. Furin J J, Mitnick C D, Shin S S, et al. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2001; 5: 648-655.
5. Holdiness M R. Neurological manifestations and toxicities of the antituberculosis drugs. A review. Med Toxicol 1987; 2: 33-51.
6. Argov Z, Mastaglia F L. Drug-induced peripheral neuropathies. BMJ 1979; 1: 663-666.
7. Ellard G A. The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis. Tubercle 1984; 65: 211-227.
8. Goldman A L, Braman S S. Isoniazid: a review with emphasis on adverse effects. Chest 1972; 62: 71-77.
9. Lubing H N. Peripheral neuropathy in tuberculosis patients treated with isoniazid. Am Rev Tuberc 1953; 68: 458-461.
10. Jones W A, Jones G P. Peripheral neuropathy due to isoniazid. Lancet 1953; 1: 1073-1074.
11. Goel U C, Bajaj S, Gupta O P, Dwivedi N C, Dubey A. Isoniazid induced neuropathy in slow versus rapid acetylators: an eletrophysiological study. J Assoc Physicians India 1992; 40: 671-672.
12. Patel A M, McKeon J. Avoidance and management of adverse reactions to antituberculosis drugs. Drug Saf 1995; 12: 1-25.
13. Gibson F D Jr, Phillips S. Peripheral neuritis after long-term isoniazid. Geriatrics 1966; 21: 179-180.
14. Gohel D, Oza J J, Panicker M G. Pyridoxine and isonex. J Assoc Physicians India 1993; 41: 229.
15. Snider D E Jr. Pyridoxine supplementation during isoniazid therapy. Tubercle 1980; 61: 191-196.
16. Nisar M, Watkin S W, Bucknall R C, Agnew R A. Exacerbation of isoniazid induced peripheral neuropathy by pyridoxine. Thorax 1990; 45: 419-420.
17. Blain P G, Lane R J. Neurological disorders. In: Davies D M, Ferner R E, de Glanville H, eds. Davies's Textbook of Adverse Drug Reactions, 5th ed. London, UK: Chapman and Hall Medical, 1998: 585-629.
18. Nair V S, LeBrun M, Kass I. Peripheral neuropathy associated with ethambutol. Chest 1980; 77: 98-100.
19. Forester D. Toxic effects of ethambutol. Chest 1980; 78: 496-497.
20. Takeuchi H, Takahashi M, Tarui S, Sanagi S, Takenada H. Peripheral nerve conduction function in patients treated with antituberculotic agents, with special reference to ethambutol and isoniazid. Folia Psychiatr Neurol Jpn 1980; 34: 57-64.
21. Poole G W, Schneeweiss J. Peripheral neuropathy due to ethionamide. Am Rev Respir Dis 1964; 84: 890-892.
22. Leggat P O. Ethionamide neuropathy. Tubercle 1962; 43: 95-96.
23. Rivlin R S. Disorders of vitamin metabolism: deficiencies, metabolic abnormalities, and excesses. In: Wyngaarden J B, Smith L H, Bennett J C, eds. Cecil Textbook of Medicine. 19th ed. Philadelphia, PA: WB Saunders Co, 1992: pp 1170-1183.
24. Hedenmalm K, Spigset O. Peripheral sensory disturbances related to treatment with fluoroquinolones. J Antimicrob Chemother 1996; 37: 831-837.
25. Aoun M, Jacquy C, Debusscher L, et al. Peripheral neuropathy associated with fluoroquinolones. Lancet 1992; 340: 127.
26. Farmer P E, Bayona J, Shin S, et al. Preliminary results of community-based MDR-TB treatment in Lima, Peru. Int J Tuberc Lung Dis 1998; 2 (Suppl 2): S371.
27. Farmer P E, Walton D A, Becerra M C. International tuberculosis control in the 21st century. In: Friedman L N, ed. Tuberculosis: current concepts and treatment, 2nd ed. Boca Raton, FL: CRC Press, 2000: pp 475-496.
28. Becerra M C, Freeman J, Bayona J, et al. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2000; 4: 108-114.
29. New York Department of Health. TB clinical policies and protocols. Oct 29, 1999. http://NYC.gov/html/doh/html/tb/cpp5.html
30. Galer B S. Neuropathic pain of peripheral origin: advances in pharmacologic treatment. Neurology 1995; 45 (Suppl 9): S17-S25.